湖北均瑶大健康饮品股份有限公司 == == 2024 年度独立董事沐职报告 作为湖北均瑶大健康饮品股份有限公司(以下简称"公司")的 独立董事,本人严格按照《公司法》、《证券法》、《上市公司独立董事 管理办法》、《上海证券交易所股票上市规则》《公司章程》、《独立董 事工作制度》等相关法律法规和规章制度的规定及要求,勤勉尽责, 审慎行使独立董事权利。现将 2024年度履行职责情况报告如下: 一、独立董事基本情况 1、工作履历、专业背景以及兼职情况 甘丽凝,1978年6月出生,中国国籍,无境外永久居留权,博 士学位。2008年4月至今,任职于上海大学悉尼工商学院副教授, 现任财会系执行主任;上海市商业会计学会副会长、理事;2023年8 月至今,任公司独立董事;2020年12月至今,任和元生物技术(上 海) 股份有限公司独立董事:2022年5月至今,任江苏林洋能源股 份有限公司独立董事。 2、独立性说明 本人作为公司独立董事,未在公司担任除独立董事以外的任何职 务,也未在公司主要股东公司担任任何职务,与公司以及主要股东之 间不存在利害关系或其他可能妨碍本人进行独立客观判断的关系,不 存在影响独立董事独立性的情况,符 ...

本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 证券代码：605388 证券简称：均瑶健康 公告编号：2025-022 湖北均瑶大健康饮品股份有限公司 关于计提资产减值及信用减值准备的公告 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）为更加真实、准确 地反映公司 2024 年度的财务状况和经营成果，根据《企业会计准则》和公司会 计政策相关规定，基于谨慎性原则，公司对截至 2024 年 12 月 31 日合并报表范 围内相关信用及资产进行了减值测试并计提了相应的减值准备。现将相关情况公 告如下： 一、本次计提资产减值及信用减值准备情况 为更加真实、准确地反映公司 2024 年度的财务状况和经营成果，根据《企 业会计准则》和公司会计政策相关规定，基于谨慎性原则，公司对截至 2024 年 12 月 31 日合并报表范围内相关信用及资产进行了减值测试并计提了相应的减值 准备。公司 2024 年度计提信用减值损失和资产减值损失共计-85,792,746.84 元， | 项目 | 2024 年计提减值金额 | | --- | --- ...

关于 2024 年度募集资金存放与实际使用情况的专项报告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 根据《上海证券交易所股票上市规则》、《上市公司监管指引第 2 号—— 上市公司募集资金管理和使用的监管要求》和《上海证券交易所上市公司自律监 管指引第 1 号——规范运作》等有关规定，湖北均瑶大健康饮品股份有限公司（以 下简称"公司"或"均瑶健康"）董事会对 2024 年度募集资金存放与使用情况 专项报告说明如下： 一、募集资金基本情况 （一）实际募集资金金额和资金到账时间 经中国证券监督管理委员会《关于核准湖北均瑶大健康饮品股份有限公司 首次公开发行股票的批复》（证监许可[2020]1568 号）核准，公司向社会公众 投资者发行人民币普通股（A 股）70,000,000.00 股，发行价格为每股 13.43 元， 募集资金总额 940,100,000.00 元，扣除各项发行费用后，募集资金净额为人民 币 883,560,100.00 元。截至 2020 年 8 月 12 日，公司上述募集资金已全部到位， 业经大华会计师事 ...

湖北均瑶大健康饮品股份有限公司 审 计 报 告 众环审字（2025）2300487号 目 录 起始页码 审计报告 | 财务报表 | | | --- | --- | | 合并资产负债表 | 1 | | 合并利润表 | 3 | | 合并现金流量表 | 4 | | 合并股东权益变动表 | 5 | | 资产负债表 | 7 | | 利润表 | 9 | | 现金流量表 | 10 | | 股东权益变动表 | 11 | | 财务报表附注 | 13 | 审 计 报 告 众环审字（2025）2300487 号 湖北均瑶大健康饮品股份有限公司全体股东: 一、审计意见 我们审计了湖北均瑶大健康饮品股份有限公司(以下简称"均瑶健康公司")财务报表, 包括 2024 年 12 月 31 日的合并及公司资产负债表,2024 年度的合并及公司利润表、合并及 公司现金流量表、合并及公司股东权益变动表以及相关财务报表附注。 我们认为,后附的财务报表在所有重大方面按照企业会计准则的规定编制,公允反映了 均瑶健康公司 2024 年 12 月 31 日合并及公司的财务状况以及 2024 年度合并及公司的经营成 果和现金流量。 二、形成审计意见的基础 ...

一、 召开会议的基本情况 证券代码：605388 证券简称：均瑶健康 公告编号：2025-020 湖北均瑶大健康饮品股份有限公司 关于召开2024年年度股东大会的通知 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： (一)股东大会类型和届次 2024年年度股东大会 (四)现场会议召开的日期、时间和地点 召开的日期时间：2025 年 5 月 23 日 14 点 00 分 召开地点：上海市浦东新区康桥东路 2 弄 1 号楼大会议室 股东大会召开日期：2025年5月23日 本次股东大会采用的网络投票系统：上海证券交易所股东大会网络投票 系统 (二)股东大会召集人：董事会 (三)投票方式：本次股东大会所采用的表决方式是现场投票和网络投票相结合的 方式 (五)网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 网络投票起止时间：自2025 年 5 月 23 日 至2025 年 5 月 23 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投票时间为股 东大会召开当日的交易时间 ...

证券代码：605388 证券简称：均瑶健康 公告编号：2025-013 湖北均瑶大健康饮品股份有限公司 第四届监事会第十次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、监事会会议召开情况 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）第四届监事会第 十次会议于 2025 年 4 月 29 日下午在公司会议室以现场会议方式召开，本次会议 通知于 2025 年 4 月 18 日以电子邮件形式送达公司全体监事。本次会议由监事会 主席林乃机先生主持。会议应出席监事 3 人，实际出席监事 3 人。本次会议的召 开符合《公司法》和《公司章程》等有关规定。 二、监事会会议审议情况 （一）审议通过《关于 2024 年度监事会工作报告的议案》 表决结果：同意：3 票；反对：0 票；弃权：0 票。 此议案尚需提交股东大会审议。 （二）审议通过《关于 2024 年度财务决算报告的议案》 表决结果：同意：3 票；反对：0 票；弃权：0 票。 有利于公司的持续、稳定、健康发展，不存在损害公司及全体股东特别是中小股 东利益的情形。 ...

二、董事会会议审议情况 （一）审议通过《关于 2024 年度总经理工作报告的议案》 证券代码：605388 证券简称：均瑶健康 公告编号：2025-012 湖北均瑶大健康饮品股份有限公司 第五届董事会第十二次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）第五届董事会第十 二次会议于 2025 年 4 月 29 日上午在公司会议室以现场方式召开，本次会议通知 于 2025 年 4 月 18 日通过邮件方式发送公司全体董事。本次会议由公司董事长王 均豪先生主持。会议应出席董事 9 人，实际出席董事 9 人，公司监事和高级管理 人员列席了本次会议。本次会议的召开符合《公司法》和《公司章程》等有关规 定。 表决结果：同意：9 票，反对：0 票，弃权：0 票。 （二）审议通过《关于 2024 年度董事会工作报告的议案》 表决结果：同意：9 票，反对：0 票，弃权：0 票。 此议案尚需提交股东大会审议。 （三）审议通过《关于审计委员会 2024 年度 ...

证券代码：605388 证券简称：均瑶健康 公告编号：2025-014 湖北均瑶大健康饮品股份有限公司 关于 2024 年度利润分配预案的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： ●每 10 股派发现金红利 0.80 元（含税）。 ●本次利润分配以实施权益分派股权登记日登记的总股本（扣除回购专户上 已回购股份数）为基数，具体日期将在权益分派实施公告中明确。 ●在实施权益分派的股权登记日前公司总股本（扣除回购专户上已回购股份 数）发生变动的，拟维持每股分配金额不变，相应调整分配总额，并将另行公告 具体调整情况。 ●本次利润分配预案不触及《上海证券交易所股票上市规则》第 9.8.1 条第一 款第（八）项规定的可能被实施其他风险警示的情形。 一、2024 年度利润分配预案的主要内容 （一）利润分配方案的具体内容 经中审众环会计师事务所（特殊普通合伙）审计，截至 2024 年 12 月 31 日， 湖北均瑶大健康饮品股份有限公司（以下简称"公司"）归属于上市公司股东的 净利润为-29,116,350.88 ...

Financial Performance - The company's revenue for Q1 2025 was CNY 401,482,952.19, representing a year-over-year increase of 1.41% compared to CNY 395,905,330.07 in the same period last year[4] - Net profit attributable to shareholders decreased by 58.29% to CNY 10,907,104.58 from CNY 26,150,321.80 in the previous year[4] - The net profit after deducting non-recurring gains and losses dropped by 70.46% to CNY 7,029,713.48 from CNY 23,794,077.50 year-over-year[4] - Basic and diluted earnings per share fell by 50.00% to CNY 0.02 from CNY 0.04 in the same period last year[4] - Total operating revenue for Q1 2025 was ¥401,482,952.19, a slight increase of 1.46% compared to ¥395,905,330.07 in Q1 2024[26] - Net profit for Q1 2025 was ¥9,622,479.68, down 62.5% from ¥25,691,096.53 in Q1 2024[27] - The company reported a total profit of ¥13,081,988.48 for Q1 2025, down from ¥34,518,629.33 in Q1 2024, a decline of 62.1%[27] Assets and Liabilities - Total assets at the end of the reporting period were CNY 2,173,223,750.91, a decrease of 6.06% from CNY 2,313,498,343.10 at the end of the previous year[5] - Current assets decreased to CNY 958,327,705.52 from CNY 1,080,864,363.47, primarily due to a reduction in cash and inventory[21] - Total liabilities decreased to CNY 406,847,133.40 from CNY 548,716,746.59, indicating improved financial stability[23] - The company's equity attributable to shareholders increased slightly to CNY 1,775,791,250.52 from CNY 1,772,911,604.62[23] Cash Flow - The company reported a net cash flow from operating activities of CNY -97,063,782.94, an improvement from CNY -129,488,834.36 in the previous year[4] - Cash flow from operating activities showed a net outflow of ¥97,063,782.94 in Q1 2025, an improvement from a net outflow of ¥129,488,834.36 in Q1 2024[29] - Cash and cash equivalents at the end of Q1 2025 were ¥123,633,938.76, down from ¥225,990,046.68 at the end of Q1 2024[30] - Investment activities generated a net cash inflow of ¥4,953,107.36 in Q1 2025, contrasting with a net outflow of ¥78,431,446.71 in Q1 2024[30] Expenses - Total operating costs increased to ¥391,483,113.73 in Q1 2025 from ¥363,845,443.70 in Q1 2024, representing a rise of 7.66%[26] - Research and development expenses increased to ¥10,076,572.33 in Q1 2025 from ¥7,328,907.08 in Q1 2024, reflecting a growth of 37.7%[26] - Sales expenses rose significantly to ¥75,040,972.82 in Q1 2025, compared to ¥42,896,126.63 in Q1 2024, marking an increase of 75.3%[26] Business Development - The decline in net profit was primarily attributed to differences in the sales cycle of probiotic beverages during the Spring Festival compared to the previous year, alongside increased expenses from ongoing investments in new business initiatives[8] - The company reported a strong development momentum in Q1 2025, with traditional beverage business stability and significant growth in the emerging probiotic sector[12] - Probiotic food revenue increased by 139.19% year-on-year in Q1 2025, demonstrating remarkable results[15] - E-commerce channel revenue surged by 1,173.33% year-on-year in Q1 2025, driven by market optimization and enhanced industry collaboration[13] - The company launched innovative probiotic beverages, including daily beauty and sleep aid products, which received multiple innovation awards[14] - The company holds a leading position in the domestic ambient yogurt market, focusing on product innovation and channel development[13] - The company has integrated its probiotic business with Yunnan Runying Biotechnology, enhancing the entire industry chain[15] - The company aims to enhance its market competitiveness through continuous innovation and strategic partnerships in the health industry[17] Shareholder Information - The company has a total of 26,969 shareholders at the end of the reporting period, with the top 10 shareholders holding significant stakes[10] - The company’s repurchase account holds 14,660,000 shares, accounting for 2.44% of the total share capital at the end of the reporting period[11] Research and Development - The subsidiary Junyao Runying has over 30,000 strains in its probiotic resource library, focusing on gut health, weight management, and immune regulation[16] - The company has established partnerships with several universities to enhance its R&D capabilities, resulting in the award-winning strain Lp-G18 and the patented CCFM1166 strain[17] Supply Chain and Operations - The integration of supply chain management and big data has improved operational efficiency, optimizing order processing, inventory management, and logistics[18]

Financial Performance - The company reported a net profit attributable to shareholders of -29,116,350.88 RMB for 2024, with a distributable profit of 424,155,504.86 RMB at the end of the reporting period[6]. - The company's operating revenue for 2024 was CNY 1,458,166,483.96, a decrease of 10.77% compared to CNY 1,634,102,031.54 in 2023[24]. - The net profit attributable to shareholders for 2024 was CNY -29,116,350.88, representing a decline of 150.57% from CNY 57,575,881.73 in 2023[24]. - The cash flow from operating activities for 2024 was CNY 32,645,604.62, down 61.95% from CNY 85,795,398.12 in 2023[24]. - The total revenue for the company reached approximately ¥1.45 billion, representing a year-over-year increase of 30.38%[69]. - The gross margin for the overall business was reported at 30.38%, with a year-over-year decrease of 10.87%[69]. - The company achieved total revenue of CNY 1,458,166,483.96, a year-on-year decrease of 10.77%[64]. - The net profit attributable to shareholders was a loss of CNY 29,116,350.88, representing a year-on-year decline of 150.57%[64]. Dividend and Shareholder Returns - A cash dividend of 0.08 RMB per share (before tax) is proposed, amounting to a total of 46,865,920.00 RMB (before tax) based on 585,824,000 shares[6]. - The company aims to maintain a stable dividend distribution policy to protect investors' rights and interests[6]. - The company has implemented a cash dividend policy, with a cumulative cash dividend amount of 132,486,920.00 CNY over the last three accounting years[192]. - The proposed cash dividend for 2024 is 0.08 CNY per share (tax included), with a total cash dividend distribution amounting to 46,865,920.00 CNY based on 585,824,000 shares[189]. Research and Development - In 2024, the company increased its R&D investment by 38% and expanded its R&D team by 19%[36]. - The company increased its R&D investment by 34% in 2024, achieving multiple domestic breakthroughs in the probiotic field, including four international awards for its plant-based Lactobacillus Lp-G18 strain[41]. - The total R&D expenditure amounted to CNY 34,642,214.07, which is 2.38% of total revenue[86]. - The company is investing in new technology development, allocating 100 million yuan towards R&D for enhancing product quality and production efficiency[165]. Market Expansion and Sales Strategy - E-commerce channel sales grew by 177.49% year-on-year in 2024[38]. - The company plans to continue expanding its overseas market presence and improve product quality and service levels[62]. - The company is focusing on new retail ecosystem development and channel construction in new traffic areas, leveraging its existing sales network for omnichannel sales[49]. - The company plans to enhance its e-commerce strategy by optimizing operations and integrating online and offline resources[120]. - The company is exploring digital marketing strategies, achieving over 76 million total exposures through various channels and collaborations with influencers in 2024[43]. Operational Efficiency and Production - The company has established a complete quality system for raw material procurement, ensuring compliance with quality requirements and delivery standards[109]. - The company has integrated several unique functional strains into its product offerings, creating a high technological barrier and developing a core product matrix for future growth[49]. - The company is enhancing its production capabilities through automation and digital management systems to improve efficiency and reduce costs[153]. - The company operates its own factories in Yichang and Quzhou, but faces capacity constraints that limit production during peak seasons[54]. Governance and Management - The company has a governance structure in place that includes a shareholders' meeting, board of directors, and supervisory board, ensuring clear division of responsibilities and improved management efficiency[158]. - The company has approved various resolutions in its shareholder meetings, including financial reports and profit distribution plans, demonstrating active governance and strategic planning[159]. - The management team includes experienced professionals with significant backgrounds in finance and management, enhancing strategic decision-making capabilities[164]. - The company has established a fair and transparent performance evaluation and incentive mechanism for senior management, conducting monthly assessments[197]. Risks and Challenges - There are no significant risks that could materially affect the company's production and operations during the reporting period[10]. - The company is facing risks from intensified market competition and fluctuations in raw material prices, which could impact profit margins[154]. - Consumer confidence has declined due to consumption downgrade, affecting actual demand and company performance; there is a need for product diversification and health-oriented features to maintain competitiveness[156]. - The company has not faced any penalties from securities regulatory agencies in the past three years[173].